NIKKEI 225
28,333.52 +209.24 (+0.74%) HANG SENG
24,218.03 -165.29 (-0.68%) CRUDE OIL
84.26 +0.44 (+0.52%) GOLD FUTURES
1,818.20 +1.70 (+0.09%) DOW
35,911.81 -201.79 (-0.56%) BTC-GBP
30,949.43 -807.97 (-2.54%)
InflaRx N.V. (IFRX)
| Previous close | 4.0900 |
| Open | 3.9400 |
| Bid | 4.2200 x 800 |
| Ask | 4.3100 x 2200 |
| Day's range | 3.9400 - 4.2900 |
| 52-week range | 2.2300 - 6.3800 |
| Volume | |
| Avg. volume | 3,020,290 |
| Market cap | 187.792M |
| Beta (5Y monthly) | 0.71 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.2570 |
| Earnings date | 23 Mar 2022 - 28 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.56 |
- Globe Newswire
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
Regulatory discussions on Phase I program have been initiatedFirst-in-human study expected to start in the second half of 2022 JENA, Germany, Jan. 10, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced a new pipeline program, INF904, an oral small molecule inhibitor of C5aR. “Inhibition of the C5a/C5aR axis provides strong anti-inflammatory effects in a vari
- Globe Newswire
InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events
Presentation at J.P. Morgan Healthcare Conference on January 13thCorporate presentation for H.C. Wainwright BioConnect Conference available online starting January 10thCompany to host virtual R&D Event on vilobelimab in Hidradenitis Suppurativa on February 3rd JENA, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced its participation at sev
- Globe Newswire
InflaRx Initiates Phase III Clinical Program with Vilobelimab in Hidradenitis Suppurativa
Phase III study to include a new primary endpoint, the modified HiSCRNew primary endpoint and Phase III trial design to be discussed in detail at virtual R&D event on February 3rdPhase III program to focus on HS patients with active draining tunnels and will start enrolling patients in Q2 JENA, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today annou
